论文部分内容阅读
目的:探讨肺癌患者化疗前后血清TGF-β1水平的临床意义。方法:采用酶联法对39例肺癌患者进行化疗前后的血清TGF-β1水平测定,并与39名正常健康人作比较。结果:化疗前肺癌组患者血清TGF-β1水平(33.8±2.4)ug/L显著高于对照组(7.4±1.6)ug/L,P<0.05,差异有统计学意义。化疗后肺癌组患者血清TGF—β1水平(10.5±2.6)ug/L显著高于对照组(7.4±1.6)ug/L,P<0.05,差异有统计学意义。结论:肺癌患者化疗前后血清TGF—β1水平的变化与肿瘤的发生、发展密切相关。
Objective: To investigate the clinical significance of serum TGF-β1 level in patients with lung cancer before and after chemotherapy. Methods: Serum levels of TGF-β1 in 39 patients with lung cancer before and after chemotherapy were determined by enzyme-linked immunosorbent assay (ELISA) and compared with 39 healthy controls. Results: The serum level of TGF-β1 in the lung cancer group before chemotherapy (33.8 ± 2.4) ug / L was significantly higher than that in the control group (7.4 ± 1.6) ug / L, P <0.05, the difference was statistically significant. The level of serum TGF-β1 in the lung cancer patients after chemotherapy (10.5 ± 2.6) ug / L was significantly higher than that in the control group (7.4 ± 1.6) ug / L, P <0.05. The difference was statistically significant. Conclusion: The change of serum TGF-β1 level in patients with lung cancer before and after chemotherapy is closely related to the occurrence and development of tumor.